Official Title: “Effects of Allopurinol on Diastolic Function in Chronic Heart Failure Patients”

In patients with chronic heart failure (CHF)due to dilated cardiomyopathy diastolic dysfunction occurs frequently and is related to a poor outcome. We have previously shown that parameters of diastolic function significantly correlate with uric acid levels, a marker of impaired oxidative metabolism. We aimed to determine whether inhibition of xanthine oxidase with allopurinol might affect diastolic function in patients with CHF.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Intervention(s) in this Clinical Trial

• Drug: allopurinol

Primary Measures

• diastolic function uric acid levels BNP
  • Time Frame: three months
    

Inclusion Criteria:

• chronic heart failure;
• left ventricular systolic dysfunction (ejection fraction <45%)
• stable clinical conditions in the previous three months
• optimal medical therapy for CHF
• normal sinus rhythm
• written informed consent
• age >18 years

Exclusion Criteria:

• renal failure (s-creatinine >2.5 mg/dl)
• already on allopurinol
• malignancies
• chronic inflammatory diseases

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Universita di Verona

Overall Clinical Trial Officials and Contacts

Mariantonietta Cicoira, MD, PhD Principal Investigator Division of Cardiology, University of Verona, Italy  

Information obtained from ClinicalTrials.gov on September 04, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00477789

Study ID Number: 802

ClinicalTrials.gov Identifier: NCT00477789

Health Authority: Italy: Ethics Committee